Direxion Daily Pharmaceutical & Medical Bull 3X ETF
Limited financial coverage for PILL.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
PILL seeks to deliver investment results of 3x the daily performance of the S&P Pharmaceuticals Select Industry Index, a modified equal-weighted index that measures the performance of pharmaceutical companies, as defined by GICS, on the S&P Total Market Index. The fund uses derivatives and swaps to achieve its target exposure. As a levered product with daily resets, PILL is designed as a short-term trading tool and not a long-term investment vehicle.
- CEO
- Michael Davidson
- IPO
- 2017
- Employees
- 39
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on PILL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $32.15M
- Div Yield
- 0.38%
- 52W High
- $24.15
- 52W Low
- $7.49
- 50D MA
- $19.24
- 200D MA
- $14.70
- Beta
- 1.80
- RSI (14)
- 40
- Avg Volume
- 54.71K
No earnings-call transcripts are available for PILL yet.
- Free Float
- 0.0%
- Shares Outstanding
- 2.07M
- Float Shares
- 0
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 13, 06 | FALK MICHAEL | other | 1,040,106 |
| Dec 13, 06 | FALK MICHAEL | other | 67,233 |
| Apr 16, 06 | FALK MICHAEL | other | 3,333 |
| Aug 28, 06 | MCGUIRE JAMES | other | 0 |
| Sep 6, 05 | MCGUIRE JAMES | other | 0 |
| May 10, 05 | FALK MICHAEL | other | 148,433 |
| Aug 1, 05 | FALK MICHAEL | other | 1,040,106 |
| Dec 8, 04 | MCNAMARA KEVIN M | other | 75,000 |
| Jan 18, 05 | MCNAMARA KEVIN M | other | 25,000 |
| Dec 21, 04 | MCNAMARA KEVIN M | other | 75,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PILL coverage
Recent articles, reports, and earnings notes.
No research on PILL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PILL report →Top Performing Leveraged/Inverse ETFs: 06/14/2026
etftrends.com · Jun 16
Top Performing Leveraged/Inverse ETFs: 12/14/2025
etftrends.com · Dec 16
Top Performing Leveraged/Inverse ETFs: 11/16/2025
etftrends.com · Nov 19
As M&A Deals Rise, Can Biotech Pharma Break Loose?
etftrends.com · Sep 19
Top Performing Leveraged/Inverse ETFs: 08/17/2025
etftrends.com · Aug 19
CURE: Make an Adventurous Bet on an Undervalued Sector
etftrends.com · Aug 12
Top Performing Leveraged/Inverse ETFs: 07/28/2024
etftrends.com · Jul 30
Top Performing Leveraged/Inverse ETFs: 07/14/2024
etftrends.com · Jul 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.